FDA Determines Regulatory Review Period for PRADAXA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of PRADAXA, a human drug product, in accordance with federal regulations and following a submission to the US Department of Commerce.